A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies

作者：Warnke Patrick H^*; Humpe Andreas; Strunk Dirk; Stephens Sebastien; Warnke Frauke; Wiltfang Joerg; Schallmoser Katharina; Alamein Mohammad; Bourke Robert; Heiner Peter; Liu Qin

来源：Journal of Cranio-Maxillofacial Surgery, 2013, 41(2): 153-161.

DOI：10.1016/j.jcms.2012.07.003

• Human mesenchymal stem cells
• MSC
• Tissue engineering
• Clinically-applicable practice
• Regenerative
• Regeneration
• FCS
• Stem cell
• Translational
• Protocol

The transplantation of human stem cells seeded on biomaterials holds promise for many clinical applications in cranio-maxillo-facial tissue engineering and regenerative medicine. However, stem cell propagation necessary to produce sufficient cell numbers currently utilizes fetal calf serum (FCS) as a growth supplement which may subsequently transmit animal pathogens. Human platelet lysate (HPL) could potentially be utilized to produce clinical-grade stem cell-loaded biomaterials as an appropriate FCS substitute that is in line with clinically-applicable practice. The goal of this study was to investigate whether HPL can be successfully used to propagate human mesenchymal stem cells (HMSCs) seeded on clinically-approved collagen materials under clinically-applicable conditions using FCS as a control. %26lt;br%26gt;HMSCs were isolated from bone marrow and cultured in the presence of 10% FCS or 10% HPL. Characterization of HMSCs was performed by flow cytometry and through osteogenic and adipogenic differentiation assays. Proliferative capacity of HMSCs on both matrices was investigated by mitochondrial dehydrogenase assays (WST) and tissue coverage scanning electron microscopy (SEM). %26lt;br%26gt;The isolated HMSC differentiated into osteogenic and adipogenic cells authenticating the multi-potentiality of the HMSCs. WST tests and the SEM images demonstrated that HPL was generally superior to FCS in promoting growth of seeded HMSCs. For all other tests HPL supported HMSCs at least equal to FCS. %26lt;br%26gt;In conclusion, HPL is an effective growth factor to allow expansion of clinical-grade HMSCs on clinically-approved biomaterials for maxillofacial and oral implantology applications.

• 出版日期2013-3